ISRAEL JOURNAL OF

 

VETERINARY MEDICINE                        home    archive    journal

Vol. 56 (2) 2001

THE USE OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND RECOMBINANT HUMAN ERYTHROPOIETIN IN THE TREATMENT OF SEVERE PANCYTOPENIA DUE TO CANINE MONOCYTIC EHRLICHIOSIS

I. Aroch and S. Harrus

Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, P.O. Box 12, 76100 Rehovot, Israel

  Abstract

    The chronic severe form of canine monocytic ehrlichiosis (CME) is characterized by severe pancytopenia, and carries a grave prognosis despite treatment. Treatment options are usually limited to supportive care, anti-ehrlichial drugs and blood component therapy. This case report describes for the first time successful treatment of a dog with severe chronic pancytopenia caused by CME. The treatment included a combination of haematopoietic growth factors (recombinant human granulocyte colony stimulating factor and recombinant human erythropoietin) and a long course of glucocorticoid therapy.

Canine monocytic ehrlichiosis (CME) is a tick-borne (Rhipicephalus sanguineus) disease of canids, caused by the rickettsia Ehrlichia canis, and is now recognized worldwide (1). CME consists of acute, subclinical and chronic phases. Dogs may recover from the acute phase of the disease without treatment, however some remain subclinically infected, and several months to years later may develop the severe pancytopaenic chronic stage. This pancytopaenic chronic phase of CME has a grave prognosis despite therapy (1,2,3,4,5). Hematopoietic growth factors have been proposed as a rational treatment for the chronic pancytopaenic phase (5). However, no clinical trials using this mode of therapy have been published. This report describes the successful treatment of a severely pancytopaenic dog in the chronic stage of CME, with long-term corticosteroid therapy in combination with two synthetic recombinant haematopoietic factors: human granulocyte colony stimulating factor (rhG-CSF) and human erythropoietin (rh-EPO).  

A three-year old male weimaraner dog was referred to the Hebrew University Veterinary Teaching Hospital with chief complaints of exercise intolerance for the last 3 months, fever, and a history of tick infestation. Two weeks prior to presentation, the referring veterinarian performed a complete blood count (CBC) which revealed a severe pancytopenia {white blood cells (WBC) - 0.29x103/mm3, platelets (Plt) - 2x103/mm3, red blood cells (RBC) - 3.94x106/mm3}. Serologic testing for E. canis with a commercial dot-blot enzyme-linked immunosorbent assay kit (Biogal Laboratories, Galed, Israel) was strongly positive. A presumptive diagnosis of CME was made, and the dog was treated with doxycycline (5mg/kg q12h PO for 14 days) and imidocarb-dipropionate (5mg/kg IM, single injection).

On the day of presentation (day 1) the dog’s general condition had deteriorated, it was lethargic, anorexic, emaciated and had a fever (40.60C), tachycardia (160/min), tachypnea (60/min), severe dyspnea, increased respiratory sounds and pale mucous membranes. CBC revealed severe pancytopenia (Table 1), severe anemia (RBC - 2.48x106/mm3), and no evidence of RBC regeneration in peripheral blood smears (reticulocyte count was 0%). The dog had hyperglobulinemia (globulin - 6.2g/dl), mild hypoalbuminemia (albumin — 2.4 g/dl), with an A/G ratio of 0.39. Thoracic radiographs showed signs consistent with severe bronchopneumonia. The E. canis IgG indirect immunofluorescence antibody test (IFA) titer was 1:5120. Severe chronic CME, with secondary bronchopneumonia, were diagnosed.

Table 1: Hematological values of a dog with severe chronic pancytopenia due to CME, successfully treated with hematopoietic growth factors and prednisone, during a 476 day period

Day

WBC (103/mm3)

RBC (106/mm3)

HB (g/dl)

Ht
(%)

MCV (fl)

MCH (pg)

MCHC
(g/dl)

Plt ( 103/mm3)

TS (g/dl)

1

0.2

2.84

6.4

19.5

69

22.5

32.8

6

86

4

1.0

3.24

7.4

21.4

66

22.8

34.5

30

82

10

2.1

2.66

6.1

18.0

68

22.9

33.8

12

92

11

2.7

2.97

7

20.5

69

23.5

34.1

5

80

16

2.0

2.63

6.4

18.7

71

24.3

34.2

21

80

26

1.3

2.41

5.9

17.7

73

24.4

33.3

22

72

41

1.8

2.00

5.3

16.4

82

26.5

32.3

13

74_

64

2.2

2.21

6.3

19.7

89

28.5

31.9

40

72

95

1.8

4.19

10.7

32.2

77

25.5

33.2

33

80

113

3.67

4.39

10.8

34.6

79

24.6

31.2

13

Nd

142

4.5

4.92

10.8

33.1

67

21.9

32.6

64

78

191

11.8

5.14

11.5

33.7

66

22.4

34.1

3

Nd

196

11.4

5.91

12.6

38.0

64

21.3

33.1

21

88

212

19.3

5.13

12.8

32.4

63

24.9

39.5

92

90

356

9.2

5.98

12.6

35.8

60

21.0

35.1

251

90

476

15.4

6.66

14.9

0.426

64

22.3

34.9

378

74

Reference intervals

5.5-17

5.5-8.5

12-18

37.0-55.0

55-77

19.5-24.5

32-36 </